Skip to Content

Join the 'Idiopathic (Immune) Thrombocytopenic Purpura' group to help and get support from people like you.

Idiopathic (Immune) Thrombocytopenic Purpura News

Related terms: Immune Thrombocytopenic Purpura, ITP

FDA Approves Tavalisse (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia

Posted 18 Apr 2018 by

SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ – Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved Tavalisse (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Tavalisse is an ...

FDA Extends Use of Promacta (eltrombopag) in Pediatric Patients with Immune Thrombocytopenic Purpura

Posted 24 Aug 2015 by

August 24, 2015 – The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove th ...

Promacta Approval Expanded to Kids With Rare Blood Disorder

Posted 24 Aug 2015 by

MONDAY, Aug. 24, 2015 – U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). ITP is characterized by a low blood platelet count. Promacta is now approved for the disorder among children who have had unsatisfactory results with other ...

FDA Approves Promacta for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication

Posted 14 Jun 2015 by

SAN DIEGO, June 12, 2015 --(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids, ...

Ask a Question

Further Information

Related Condition Support Groups


Related Drug Support Groups

prednisone, cortisone, triamcinolone, dexamethasone, cyclosporine, rituximab, azathioprine, Decadron, Kenalog-40, view more... RhoGAM, Gammagard, Nplate, Deltasone, Gamunex, Privigen, Gamunex-C, interferon alfa-2b, immune globulin intravenous, Promacta, romiplostim, Dexone, Adrenocot LA, Intron A, Octagam, Carimune, Sterapred DS, Liquid Pred, Tavalisse, Adrenocot, rho (d) immune globulin, Rhophylac, eltrombopag, Sterapred, BayRHo-D Mini-Dose, BayRHo-D Full Dose, D-Gam Anti-D, fostamatinib, Liberim D, HyperRHO S / D Full Dose, WinRho SDF, Carimune NF, HyperRHO S / D Mini-Dose, BayRHo-D, Gamimune, Partobulin SDF, immune globulin intravenous and subcutaneous, Dexamethasone Intensol, Mini-Gamulin Rh, Baycadron, Dalalone, Dalalone DP, Dalalone LA, Decaject, Decaject LA, Gammaplex, Gammar IV, Zema Pak, Gammaked, Zonacort, LoCort, HypRho-D Mini-Dose, Gamulin Rh, De-Sone LA, Prednicen-M, Dexacort-LA, Dexasone, Dexasone LA, Solurex, Dexone LA, Primethasone, Dexacorten, Medidex, Medidex LA, Dexpak Taperpak, Dexacen-4, Meticorten, Solurex LA, Orasone, Decadron-LA, Flebogamma, Polygam S / D, Panglobulin NF, MICRhoGAM, Iveegam En, Panglobulin, Gamimune N 10%, Gamimune N 5%, Gammar-P IV, Prednicot, Venoglobulin-S 10%, Venoglobulin-S 5%, Sandoglobulin, Gammagard S / D, Hexadrol, Cortone Acetate, Clinacort